# Inner-City Anti-IgE Therapy for Asthma

> **NCT00377572** · PHASE4 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 419 (actual)

## Conditions studied

- Asthma

## Interventions

- **BIOLOGICAL:** omalizumab
- **BIOLOGICAL:** omalizumab placebo

## Key facts

- **NCT ID:** NCT00377572
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 419 (ACTUAL)
- **Last updated:** 2017-03-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00377572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00377572, "Inner-City Anti-IgE Therapy for Asthma". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00377572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*